Dynamic expression of Qa-2 during acute graft rejection.
نویسندگان
چکیده
Human leukocyte antigen (HLA)-G exhibits immunotolerogenicity and is related to allograft acceptance. Qa-2 is the murine homolog of HLA-G; it has structure and functions similar to those of HLA-G. We investigated the dynamic expression of Qa-2 in skin allografts by immunohistochemistry and on peripheral blood lymphocyte subsets by flow cytometry during the entire process of acute graft rejection (AGR) with a murine skin transplantation model to determine its relationship with the pathological changes of allografts and the influence of immunosuppressive therapy. In grafts without immunosuppressive treatment, Qa-2 did not exhibit obvious changes in syngeneic and allogeneic recipients. In contrast, with immunosuppressant-treated grafts, positive expression of Qa-2 was observed. It remained at high levels in the immunosuppressant-treated syngeneic group; however, it became weakly positive and even negative in infiltrating inflammatory cells as AGR advanced, but it remained strongly positive in other skin tissues throughout the AGR process. Qa-2 expression on CD4(+) and CD8(+) peripheral blood lymphocyte subsets remained stable at a normal level in the non-immunosuppressant-treated syngeneic group. Immunosuppressive treatment can also significantly upregulate Qa-2. In the allogeneic groups, decreased expression was observed when AGR was at histological grades 1 to 2 (well before gross rejection was observed). Qa-2 was upregulated again after the graft was rejected completely. The results suggest that the increase in Qa-2 may be attributed to the use of immunosuppressive treatments. Moreover, Qa-2 expression decreased significantly with AGR progression, suggesting that it may be a potential marker for predicting AGR, especially in the presence of immunosuppressive agents.
منابع مشابه
Cardiomyocyte-Specific Bcl-2 Overexpression Attenuates Ischemia-Reperfusion Injury, Immune Response During Acute Rejection, and Graft Coronary Artery Disease Running title: EFFECTS OF BCL-2 ON CARDIAC ALLOGRAFT REJECTION
After cardiac transplantation, graft damage occurs secondary to ischemia-reperfusion injury and acute rejection, this damage ultimately leads to the development of graft coronary artery disease (GCAD), which limits a long-term graft survival. Apoptosis is directly involved in these graft injury, contributing to the development of GCAD. To assess the role of the anti-apoptotic factor Bcl-2 in th...
متن کاملبررسی میزان بقا پیوند کلیه در کودکان مبتلا به اختلالات دستگاه ادراری تحتانی در بیمارستان لبافینژاد
Background & Aim: Previously, patients with end stage renal failure(ESRF) and lower urinary tract abnormality(LUTA) were often considered high risk for renal transplantation. In order to examine the degree of risk, 48 patients who received renal transplants in Labafi Nejad Hospital were evaluated between 1986 and 2003. Patients & Method: In this retrospective cohort study, the mean age of t...
متن کاملIntragraft interleukin 2 mRNA expression during acute cellular rejection and left ventricular total wall thickness after heart transplantation.
OBJECTIVE To assess whether diastolic graft function is influenced by intragraft interleukin 2 (IL-2) messenger RNA (mRNA) expression in rejecting cardiac allografts. DESIGN 16 recipients of cardiac allografts were monitored during the first three months after transplantation. The presence of IL-2 mRNA in endomyocardial biopsies (n = 123) was measured by reverse transcriptase polymerase chain...
متن کاملMonocytic Tissue Transglutaminase in a Rat Model for Reversible Acute Rejection and Chronic Renal Allograft Injury
Acute rejection is a major risk factor for chronic allograft injury (CAI). Blood leukocytes interacting with allograft endothelial cells during acute rejection were suggested to contribute to the still enigmatic pathogenesis of CAI. We hypothesize that tissue transglutaminase (Tgm2), a multifunctional protein and established marker of M2 macrophages, is involved in acute and chronic graft rejec...
متن کاملنتایج بالینی اینداکشنتراپی در بیماران تحت پیوند کلیه
Background: The goal of Induction therapy is to prevent acute rejection during the early posttransplantation period by providing a high degree of Immunosuppression at the time of transplantation. Induction therapy is often considered essential to optimize outcomes, especially in patients at high risk for poor short-term outcomes. The optimal prophylactic induction immunosuppressive therapy to p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Molecular medicine
دوره 17 3-4 شماره
صفحات -
تاریخ انتشار 2011